Million-dollar boost for Evotec
06.10.2015 - Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.
The compound management agreement will run for the next five years, and could be worth up to €4.5m for the company headquartered in Hamburg. The compound collection will form a part of the Chemical Biology Consortium’s (CBC) drug discovery and development platform for oncology therapeutics. A consortium of academic and not-for-profit institutions will then research the viability of the compounds as agents targeting cancers in a number of different R&D programmes.
Mario Polywka, Chief Operating Officer of Evotec, commented: “We are pleased the NCI has elected to award Evotec this important contract to support the Chemical Biology Consortium, an important initiative in the discovery of new cancer treatments.”
The CBC was established in 2009 to facilitate the discovery and development of new agents to treat cancer. The Consortium brings together chemical biologists and molecular oncologists from government, industry and academia to address unmet needs in therapeutic oncology. Through the CBC and the interactions among the various participants, the NCI's drug discovery and development pipeline now spans from target identification through proof-of-concept clinical trials.